We are live on ! Find out more

Exagen

XGN

Market cap $172M

7.10 USD

+1.29

22.2%

At close Updated Nov 9, 4:00 PM EST

Pre-market

After hours

7.21

+0.11

1.55%

1 day

22.2%

5 days

-15.38%

1 month

-15.68%

3 months

6.93%

6 months

78.39%

Year to date

17.55%

1 year

-24.95%

5 years

-41.9%

10 years

-61.79%

About: Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

Employees: 220

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen will participate in the Canaccord Genuity MedTech & Diagnostics Conference November 11 and the Craig-Hallum Alpha Select Conference November 17

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen to Announce Third Quarter Financial Results on November 10, 2026

CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2026, before the market opens on Tuesday, November 10, 2026.

Exagen to Announce Third Quarter Financial Results on November 10, 2026

Exagen: The Path To Profitability Just Became More Credible

Exagen delivered a standout quarter, with 16% revenue growth, record ASP, and near-breakeven adjusted EBITDA, reinforcing the turnaround thesis. XGN raised full-year revenue guidance to $72-75M, with Pharma Services revenue tripling and backlog growing, highlighting new long-term growth levers. Operating margin improved to -8.6%, and Q2 cash generation turned positive, signaling tangible progress toward profitability and improved liquidity.

Exagen: The Path To Profitability Just Became More Credible

Exagen Q2 Earnings Call Highlights

Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even.

Exagen Q2 Earnings Call Highlights

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. Reports Second Quarter 2026 Financial Results

Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates.

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen Inc. to Participate in Upcoming Investor Conference

CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord Genuity 46 th Annual Growth Conference – Boston, MA Date: August 11, 2026Fireside Chat at 8:30am ETA live and archived webcast of the Fireside Chat will be available on Exagen's Investor Relations website at investors.exagen.com.

Exagen Inc. to Participate in Upcoming Investor Conference

Exagen: A Small Diagnostics Company Approaching An Inflection Point

Exagen earns a Buy rating as revenue growth accelerates, ASPs improve, and break-even appears within reach despite ongoing cash burn. XGN leverages a growing proprietary autoimmune diagnostics database, positioning itself for long-term strategic value through AI-driven insights and biopharma partnerships. Gross margins remain stable near 60%, with breakeven targeted at $80M sales and 63% margins, achievable by 2027 if 10% annual growth continues.

Exagen: A Small Diagnostics Company Approaching An Inflection Point

Exagen to Announce Second Quarter Financial Results on August 4, 2026

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026.

Exagen to Announce Second Quarter Financial Results on August 4, 2026

See News Rankings

Price charts implemented using Lightweight Charts™